N-(1-(S)-cyano-3-phenyl-propyl)-2,2-difluoro-4-phenyl-butyramide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: N-(1-(S)-cyano-3-phenyl-propyl)-2,2-difluoro-4-phenyl-butyramide
• 英文别名: N-[(1S)-1-cyano-3-phenylpropyl]-2,2-difluoro-4-phenylbutanamide
• 化学式: C₂₀H₂₀F₂N₂O
• 分子量: 342.4
• InChiKey: TVRADSFMTXVZLV-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-cyano-3-phenyl-propylamine hydrochloride 、 2,2-Difluoro-4-phenylbutanoic acid 、 2,2-Difluoro-4-phenyl-butyramide 在 N-1-(S)-cyano-3-phenyl-propyl 作用下， 生成 N-(1-(S)-cyano-3-phenyl-propyl)-2,2-difluoro-4-phenyl-butyramide
  参考文献：
  名称：

  Novel compounds and compositions as cathepsin inhibitors

  摘要：

  本发明涉及一种新型选择性卡硫化酶S抑制剂，其药学上可接受的盐和N-氧化物，其作为治疗剂的用途以及其制备方法。

  公开号：

  US20040142999A1

文献信息

• CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1397340A2

  公开（公告）日：2004-03-17
• QUINOLINONE DERIVATIVES FOR TREATING CELL PROLIFERATION RELATED DISORDERS
  申请人：Amgen Inc.

  公开号：EP1478645A2

  公开（公告）日：2004-11-24
• USE OF CATHEPSIN S INHIBITORS FOR TREATING AN IMMUNE RESPONSE CAUSED BY ADMINISTRATION OF A SMALL MOLECULE THERAPEUTIC OR BIOLOGIC
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1694357A1

  公开（公告）日：2006-08-30
• [EN] NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS<br/>[FR] NOUVEAUX COMPOSES ET COMPOSITIONS UTILISES EN TANT QU'INHIBITEURS DE CATHEPSINE
  申请人：AXYS PHARM INC

  公开号：WO2002098850A2

  公开（公告）日：2002-12-12

  The present invention relates to coumponds of formula (I) (in which X1 is-NHC(R1)(R2)X3 or -NHX4 and the other variables are as defined in the claims) and the pharmaceutically acceptable salts and N-oxides therof, useful as selective cathepsin S inhibitors, their uses as therapeutic agents and the methods for their making. Formula (I):
• [EN] COMPOUNDS AND METHODS OF USES<br/>[FR] COMPOSES ET PROCEDES D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2003066630A2

  公开（公告）日：2003-08-14

  Selected compounds of formula (I) wherein (a) is (b) or (c) wherein A is O, S or NH; wherein D is CR1 or N; wherein E is CR2 or N; wherein F is CR3 or N; wherein F is CR4 or N; wherein J is selected from NR6, S, O, and CR1 wherein K is selected from NR6 , S, O, and CR2; wherein L is selected from NR6, S, O, and CR3 are effective for treatment of diseases, such as cell proliferation or apoptosis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving stroke, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.